Porcine mitral stentless valve mid-term clinical results.
OBJECTIVE
Time testing is essential with any valvular procedure, especially when a new concept is introduced such as the mitral stentless valve. Our purpose is to evaluate the results obtained over 4 years with this operation, particularly to attest the impact of preservation of annulo ventricular continuity on the long term results of these patients.


METHODS
From March 1992 to August 1996, 120 patients had their mitral valves replaced with a porcine stentless mitral valve. The observation period was 54 months with total patients follow-up of 3424 months with a mean of 28.5 months. The age ranged from 11 to 72 years (mean 35.22 +/- 14.98). There were 73 females (60.8%) and 47 males (39.2%). The predominant etiology was rheumatic heart disease. Associated procedures were performed in 12 patients (10%), and the great majority of the patients were in functional class III and IV (NYHA).


RESULTS
Hospital mortality occurred in seven patients (5.83%) non valve related except for one early case of endocarditis. Early reoperation related to technical failure were necessary in 4 patients without mortality. Follow-up was accomplished in 101 patients and ranged from 2 to 54 months. Late reoperations were required in 16 patients (nine due to mitral insufficiency, five because of endocarditis and two for mitral stenosis). Most reoperations were related to technical failure. Among the 82 patients presently in control, 72 showed a competent mitral stentless valve, eight with stable mild mitral regurgitation and in two a decreased mitral orifice. Hemodynamic performance of the valve has been excellent in this group, particularly in patients with left ventricular dysfunction.


CONCLUSIONS
Although technical complexity remains the main cause of reoperations with this valve, experience has shown that it not only provides preservation of the left ventricular function but also promised significant increase of the ejection fraction in patients with poor left ventricular function.
Vrandecic
M
M
Department of Cardio-Thoracic Surgery, Biocor Institute, Belo Horizonte, MG, Brazil.
Gontijo
B
B
Fantini
F A
FA
Martins
I
I
Oliveira
M H
MH
Avelar
S S
SS
Oliveira
O
O
Vrandecic
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001705:Bioprosthesis / Q000379:methods* / Q000401:mortality; D002648:Child; D005260:Female; D006350:Heart Valve Prosthesis / Q000379:methods* / Q000401:mortality; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D012214:Rheumatic Heart Disease / Q000601:surgery*; D015996:Survival Rate; D013552:Swine